Table 4 Secondary outcome analysis—office BP response and control rates

From: Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial

 

Amlodipine–perindopril

Perindopril–indapamide

Amlodipine–indapamide

n = 661

n = 662

n = 658

n (%)

n (%)

n (%)

Response ratea

 2-month

266 (40.2)

243 (36.7)

237 (36.0)

 4-month

301 (45.5)

302 (45.6)

307 (46.7)

 6-month

315 (47.7)

317 (47.9)

306 (46.5)

 Proportion of respondersb

266 (40.2)

260 (39.3)

248 (37.7)

Control ratec

(<140 and 90 mmHg)

 2-month

424 (64.1)

411 (62.1)

417 (63.4)

 4-month

464 (70.2)

478 (72.2)

470 (71.4)

 6-month

470 (71.1)

486 (73.4)

454 (69.0)

 Proportion with BP controld

440 (66.6)

457 (69.0)

429 (65.2)

Control ratec

(<130 and 80 mmHg)

 2-month

221 (33.4)

196 (29.6)

199 (30.2)

 4-month

267 (40.4)

266 (40.2)

285 (43.3)

 6-month

282 (42.7)

274 (41.4)

262 (39.8)

 Proportion with BP controld

194 (29.3)

195 (29.5)

191 (29.0)

  1. Office BP was measured at baseline and at 2 months, 4 months and 6 months (the average of the last two of three office BP readings is used).
  2. aThe response rate is the proportion of patients with a reduction in office SBP ≥20 mmHg and office DBP ≥10 mmHg at a given time.
  3. bThe proportion of patients classified as ‘responders’ is defined as those who had a reduction of office SBP ≥20 mmHg and office DBP ≥10 mmHg at any of their office visits, with maintenance of this reduction at the 6-month office visit.
  4. cThe control rate is the proportion of patients with an office BP of less than (140 and 90 mmHg or 130 and 80 mmHg) at a given time.
  5. dThe proportion of patients who achieve BP control is defined as achieving target BP (less than 140 and 90 mmHg or 130 and 80 mmHg) at any of their office visits, with maintenance of this reduction at the 6-month office visit.
Back to article page